Brief: Centogene And Denali Therapeutics Extend Observational Study On Parkinson’s Disease Genetics
09/01/2023 13:58
Jan 9 (Reuters) - Centogene NV 39K.MU :
* CENTOGENE AND DENALI THERAPEUTICS EXTEND WORLD’S LARGEST
OBSERVATIONAL STUDY ON PARKINSON’S DISEASE GENETICS
* NEXT PHASE OF ROPAD STUDY WILL FOCUS ON 48 TARGETED SITES
ACROSS
10 COUNTRIES
Source text for Eikon: ID:nGNXbtLvT9
Further company coverage: 39K.MU
((Reuters.Briefs@thomsonreuters.com))
Recent news on Crown LiquidationCo NV in liquidatie
See all newsBrief: Centogene Signs Strategic Transaction With Private Equity Group Charme Capital Partners
Brief: Centogene Announces Adoption Of All Resolutions Tabled At 2024 Annual General Meeting
Brief: Centogene NV Says Agreements With LIFERA Provides Funding In Aggregate Of About $20 Mln To Co
Brief: Centogene And Evotec Discover Promising New Molecule To Treat Gaucher Disease
Brief: Centogene Receives Nasdaq Non-Compliance Notice